Introduction
Sirtuins, a conserved protein family, are identified to have the deacylase and/or mono-ADP-ribosyltransferase activities [
1]. Sirtuins have been implicated in a variety of physiological processes, including transcription, DNA repair, tumorigenesis, metabolism, stress responses, apoptosis, fat mobilization, and aging [
2]. Among seven identified members (SIRT1-7) of these histone deacetylases, sirtuin 6 (SIRT6) has been shown to be involved in cellular pathways and to play a critical role in regulating ageing and sugar metabolism, both of which are associated with the occurrence and development of tumours and are thus significantly associated with cancer patient prognosis [
3,
4]. Against this background, SIRT6 is considered to be a regulator in the progression of cancer and thus affect the survival rate of cancer patients.
SIRT6 expression levels vary significantly between tumour types. Researches reveal that SIRT6 is overexpressed in osteosarcoma [
5], papillary thyroid cancer (PTC) [
6], prostate cancer [
7], conversely reduced in renal cell carcinoma (RCC) [
8], pancreatic ductal adenocarcinoma (PDAC) [
9], colon cancer (CRC) [
10], non-small cell lung cancer (NSCLC) [
11]. On the other hand, SIRT6 is thought to play a role in or suppress the progression of several types of cancer. For example, immunohistochemistry revealed that SIRT6 expression was considerably lower in tumour tissues than in normal tissues in RCC patients, implying that SIRT6 worked as a tumour suppressor [
8]. Loss of SIRT6 expression in human PDAC defined a subset of patients with a worse prognosis [
9]. Moreover, Lower SIRT6 levels were demonstrated in colon cancer and were associated with shorter survival than those of patients with higher SIRT6 expression [
10].
In comparison, patients with osteosarcoma who express a high level of SIRT6 exhibit malignant clinical features and have a worse survival rate, with in vitro experiments indicating that SIRT6 overexpression aided MG63 cell motility and invasion [
5]. In NSCLC cell lines and tumor tissues, SIRT6 is proved to be upregulated, and statistical analyses showed that high SIRT6-expressing NSCLC patients had a lower cumulative survival rate as compared with low SIRT6-expression patients [
11]. SIRT6 upregulation was associated with poor recurrence-free survival (RFS) in PTC patients, given that patients with the higher expression of SIRT6 had the worse RFS and those who possessed lower expression of the gene had the better RFS [
6]. Besides, high SIRT6 expression was associated with poor OS of gastric cancer [
12].
As a result, while the molecular pathways behind SIRT6 have been explored, the relationship between SIRT6 expression and the prognosis of patients with solid malignancies remains contentious. The goal of this study is to further elucidate the role of SIRT6 in mammalian solid tumours by meta-analysis and the TCGA dataset, which may aid in the detection and treatment of certain cancers.
Materials and methods
Study research
We conducted an electronic literature search of all publications in the PubMed and ISI Web of Science databases to determine whether there is a correlation between SIRT6 expression and survival in solid tumours. The research was terminated on August 15, 2021, with no lower date limit. Sirtuin 6, SIRT6, cancer, tumour, prognosis, prognostic, and survival were all included in the search terms in all possible combinations. Searches were limited to human studies and those published in English.
Inclusion and exclusion criteria
The included studies had to meet the following criteria: (1) to be published in its entirety in the English language; (2) to make a pathological diagnosis of cancer; (3) to describe the pathological diagnosis of various tumour types or clinicopathological features; (4) to measure SIRT6 expression in patients with any type of tumour via immunohistochemistry; (5) to describe associations between SIRT6 expression and OS and DFS; and (6) to report or calculate HRs and 95% CIs based on the information in the pamphlet.
The following criteria were used to exclude studies from this meta-analysis: (1) Reviews, letters, comments, repetitive research, case reports, or personal communications; (2) non-English language articles; (3) articles that overlap or contain duplicate data; (4) articles that contain only animal experiments; and (5) studies that do not include survival curves or data on survival.
Two investigators (Shuyuan Wang and Zhen Yuan) extracted all data independently based on the inclusion and exclusion criteria, and all items were finally agreed upon. The following characteristics were extracted for each eligible study: the first author’s name, the publication year, the region, the type of cancer, the number of patients, the duration of follow-up, the detection methods, the survival data (including OS and DFS), and clinicopathological parameters such as gender, tumour differentiation, T status, lymph node metastasis, distant metastasis, and TNM stage.
Statistical analysis
Stata 16.0 (Stata Corporation, College Station, TX, USA) was used to conduct this meta-analysis. The association between SIRT6 expression and survival outcome was evaluated using pooled HR estimates with 95% CIs, while the association with clinical parameters such as gender, tumour differentiation, lymph node metastasis, distant metastasis, and clinical stage was evaluated using OR estimates with 95% CIs. Further, the Cochrane’s Q test and I
2 statistical test were used to analyze the heterogeneity between studies, the fixed effects model (Mantel–Haenszel method) was conducted when heterogeneity was negligible (I
2 < 50%), and a random effects model (DerSimonian-Laird method) was used when heterogeneity was significant (I
2 > 50%). Begg’s funnel plot was conducted to identify publication bias. All the P values were used for a two-sided test with significance at P < 0.05. The HRs and 95% CIs were extracted from articles that only reported Kaplan–Meier curves using Software Engauge Digitizer (version 10.8). Tierney et al. provided the method and EXCEL programmed for calculating the data [
13].
Extraction and analysis of TCGA dataset
The Cancer Genome Atlas (TCGA) dataset (
https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) and UCSC Xena project (
https://xena.ucsc.edu/) were used to extract the data in malignant tumors and normal tissues, including the expression of SIRT6, survival data and clinicopathological parameters. The differential expression of SIRT6 between tumours and paired normal tissues was analyzed using Wilcoxon’s signed-rank test. The OS and DFS curves were generated using the Kaplan–Meier method and the logrank test, respectively, using data from the TCGA dataset. To analyse the prognostic effects of SIRT6 in various tumours, the forest plot was mapped using univariate Cox regression. The correlation between SIRT6 expression and clinicopathological parameters were determined using a one-way ANOVA. All data were analyzed and plots were created using the R programming language (version 3.6.1).
Discussion
SIRT6, a key member of the long-lived protein family, has been shown to regulate a variety of physiological processes and is intimately involved in tumour formation and progression. The current meta-analysis, which included 15 studies and 1577 patients, was the first to summarise all previously published research on the effect of SIRT6 expression on human tumour prognosis. It established a significant association between SIRT6 expression and a decline in cancer patients’ OS (HR = 0.66, 95% CI = 0.45–0.97, P < 0.001) and DFS (HR = 0.48, 95% CI = 0.26–0.91). Low SIRT6 expression was associated with a better OS in breast cancer (HR = 0.49, 95% CI = 0.27–0.89, P = 0.179), but was associated with a worse OS in gastrointestinal tumours (HR = 0.30, 95% CI = 0.10–0.91, P = 0.069).
Additionally, multivariate analysis revealed a correlation between low cytoplasmic SIRT6 expression and improved OS (HR = 0.30, 95% CI = 0.18–0.50, P = 1.000). SIRT6 deficiency was associated with distant metastasis (OR = 2.98, 95% CI = 1.59–5.57, P = 0.694). However, no obvious correlations between decreased SIRT6 expression and other clinicopathological characteristics were observed.
Additionally, the TCGA dataset was used to assess SIRT6's prognostic value in various tumour types. The TCGA dataset revealed that decreased SIRT6 was associated with a better overall survival in all 17 types of tumours, but with a worse overall survival in gastrointestinal cancer, which was consistent with meta-analysis results. However, low SIRT6 expression has been associated with a poorer OS in head and neck cancer, urogenital cancer, and other system cancers.
The biological function of SIRT6 may help to explain the contradictory findings. The current study demonstrated that SIRT6 acts as a double-edged sword during the development of solid tumours, suppressing or promoting tumour growth, depending on the type of tumour [
25]. However, in the same tumor type, SIRT6 may also play dual roles in tumor progression by activating different signaling pathways, such as breast cancer [
26,
27] and HCC [
21]. In the context of cancer inhibition, the tumor suppression function of SIRT6 may achieved by regulating DNA repair, genomic stability, metabolic homeostasis and apoptosis [
28], of which the main mechanism was the suppression of aerobic glycolysis (a.k.a. Warburg effect), an common alteration in glucose metabolism in cancer cells [
29]. Further, upregulated SIRT6 achieves the function of tumor suppression in HCC through inhibiting phosphorylation of ERK1/2 [
30] and reducing the expression of cycling D1 and p-ERK [
31]. SIRT6 can not only upregulate the expression of tumor suppressors phosphatase and tensin (PTEN), and phosphatidylinositol-4,5-biphosphate (PIP2), but also can downregulate AKT1, mTOR, cyclin D1, and c-myc to inhibit the progression of colon cancer [
10]. The role of SIRT6 in tumour promotion has been extensively studied in recent years. SIRT6 can inhibit Bax activation caused by H3K9 deacetylation, thereby promoting HCC growth [
21]. SIRT6 promotes breast cancer by regulating the acetylation and sensitivity to lapatinib of Forkhead box protein O3 (FoxO3) [
32].
Both of SIRT6's functions in the same tumour type may be related to autophagy. Autophagy can degrade toxic proteins and dysfunctional organelles in the early stages of cancer, but in the later stages, the sensitivity of cancer cells to pressure may be reduced, which can aid in the progression of the disease and its progression [
33]. Meanwhile, SIRT6 induced DNA repair can inhibit the development of tumors in initial phase, whereas promote the growth of tumors in later phase [
28].
The results of the TCGA dataset were not entirely consistent with the conclusions of the meta-analysis, which could be attributed to any of the factors listed above. Furthermore, other factors that are not mentioned in the papers, such as the detection method, the detection phase, whether or not p53 is phosphorylated, and other factors, may contribute to the differences between the results.
The original articles included in this study were all prospective, which reduced the likelihood of selection bias and reverse causation to a great extent. A large number of cases had been gathered from various studies, and the total number of participants (1577) was significant, increasing the statistical power of the analysis. The results of the funnel plot and Begg’s analysis did not reveal any evidence of publication bias, indicating that the findings have a high degree of credibility. However, there were some mediocre imitations found in this study that were worth mentioning. The main imitation was the high heterogeneity between overall survival, disease-free survival, and various clinicopathological parameter analyses. Furthermore, subgroup analysis did not yield a clear picture of the source. According to the documents and materials available, we know that while sirtuins can be found in a variety of cellular compartments, SIRT6 is primarily found in the nucleus, where it can bind and deacylate chromatin as well as other substrates, the majority of which are transcription factors (Fig.
1) [
34‐
36]. Throughout the 15 selected studies, there are only 8 articles reported the SIRT6 location, which may be a source of high heterogeneity.
Meanwhile, other possible knockoffs should be taken into consideration as well. First and foremost, we require more trials to analyze; second, we require articles that investigate a greater variety of cancer types; third, some of the survival data was extracted from Kaplan–Meier curves, which may be less reliable than a direct analysis of variance; and fourth, we require more non-English publications to search.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.